Research Site
Leeds, West Yorkshire, LS2 9LH, United Kingdom
NCT Number: NCT02641041
The primary objective of this study is to assess the safety and tolerability of a single dose and multiple doses of BIIB033 administered to healthy adult Japanese participants. The secondary objectives of this study are to evaluate the pharmacokinetics (PK) profile of BIIB033 administered as single and multiple doses in healthy adult Japanese participants and to assess the single-dose and multiple-dose immunogenicity of BIIB033.
Looking for future studies?
Notify Me20 year–55 year
All sexes
Interventional
Phase 1
Leeds, West Yorkshire, LS2 9LH, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
single or multiple dose
single or multiple dose
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Time frame: Up to day 113
Biogen
Industry
A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03268239
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, France
View Trial DetailsNCT06683612
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
London, United Kingdom
View Trial DetailsNCT04539002
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Portland, Oregon, United States
View Trial DetailsNCT06019611
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Rochester, Minnesota, United States
View Trial Details